期刊文献+

成纤维细胞生长因子23与血液透析患者心血管疾病的关系 被引量:10

Relationship between fibroblast growth factor-23 and cardiovascular disease in hemodialysis patients
下载PDF
导出
摘要 目的探讨成纤维细胞生长因子23(FGF-23)与血液透析患者心血管疾病的关系。方法选择维持性血液透析患者共70例为研究组,匹配21例体检者为对照组。研究组又分为心血管病变组(n=24)与非心血管病变组(n=46)。所有研究对象检测采血检测血红蛋白(Hb)、白蛋白(ALB)、肌酐(Cr)、尿素氮(BUN)、尿酸(UA)、钙(Ca)、磷(P)、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、空腹血糖(FPG)、血清全段甲状旁腺激素(iPTH)、FGF-23水平。研究组对象检测C-反应蛋白(CRP)、胱抑素C(CysC)和血浆N末端B型钠尿肽前体(NT-pro BNP)水平。采用彩色多普勒超声仪对研究组患者进行心脏超声检查,计算射血分数(LVEF)和左心室质量指数(LVMI),并比较分析。结果研究组血清Hb、ALB、Ca水平低于对照组,Cr、BUN、UA、P、iPTH、FGF-23水平高于对照组,差异均有显著性(P<0.05),两组TG、TC、HDL-C、LDL-C、FPG水平无显著差异(P>0.05)。心血管病变组FGF-23、CysC、NT-pro BNP、LVMI显著高于非心血管病变组,LVEF显著低于非心血管病变组。对血液透析患者心血管疾病发生的各种检测指标的逐步Logistic回归分析发现,只有FGF-23、NT-pro BNP和CysC进入回归方程,OR分别为3.024、2.783、2.454。结论 FGF-23与维持性血液透析患者心血管病变有着密切的联系,其在预测心血管疾病发生中的价值略优于NT-pro BNP和CysC,对观察维持性血液透析患者心血管病的发生、发展具有重要的意义。 Objective To investigate the relationship between fibroblast growth factor-23(FGF-23)and cardiovascular disease in he-modialysis patients. Methods Seventy cases of maintenance hemodialysis were collected for the study group,and 21 volunteers were matched for the control group. The study group was divided into cardiovascular disease group(n = 24)and non-cardiovascular disease group(n = 46). Serum levels of blood hemoglobin( Hb),albumin( ALB),creatinine( Cr),blood urea nitrogen( BUN),uric acid( UA),calcium( Ca),phos-phorus(P),triglycerides(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL -C),low density lipoprotein cholesterol (LDL-C),fasting plasma glucose(FPG),iPTH and FGF-23 were detected in all of the subjects. Detection of C-reactive protein(CRP), cystatin C( CysC)and plasma N-terminal B-type natriuretic peptide precursor( NT-pro BNP)levels were taken in the study group. Color Doppler ultrasound was used in study group to calculate left ventricular ejection fraction( LVEF)and left ventricular mass index( LVMI),and comparative analysis was undertaken. Results Serum levels of Hb,ALB and Ca in the study group were significantly lower than the control group;Cr,BUN,UA,P,iPTH,and FGF-23 were significantly higher than the control group(all P 〈0. 05). TG,TC,HDL-C,LDL-C, FPG had no significant differences in two groups(all P 〉0. 05). FGF-23,CysC,NT-pro BNP and LVMI in cardiovascular disease group was significantly higher than non-cardiovascular disease group,and LVEF was significantly lower than non-cardiovascular disease group. On a varie-ty of indicators to detect cardiovascular disease in hemodialysis patients,stepwise logistic regression analysis showed that only FGF-23,NT-pro BNP and CysC entered the regression equation,with OR 3. 024,2. 783 and 2. 454,respectively. Conclusion FGF-23 is closely linked to car-diovascular disease in patients with maintenance hemodialysis,which is slightly better than NT-pro BNP and CysC in predicting the occurrence of cardiovascular disease and has important significance for the observation of occurrence and development of cardiovascular disease in hemodialysis patients.
出处 《临床和实验医学杂志》 2014年第19期1591-1593,共3页 Journal of Clinical and Experimental Medicine
关键词 血液透析 成纤维细胞生长因子-23 心血管疾病 Hemodialysis Fibroblast growth factor - 23 Cardiovascular disease
  • 相关文献

参考文献9

  • 1Fedak D, Bigaj K, Sutowicz W. Fibroblast growth factor - 23 ( FGF - 23). Part III. Relationship between FGF- 23 serum concentration and cardio - vascular morbidity and mortality [ J]. Przegl Lek, 2011,68 (9) :614 -618.
  • 2Seiler S, Cremers B, Rebling NM, et al. The phosphatonin fibroblast growth factor 23 links calcium - phosphate metabolism with left - ven- tricular dysfunction and atrial fibrillation [ J ]. Eur Heart J, 2011,32 (21) :2688 -2696.
  • 3Smith K, deFilippi C, Isakova T, et al. Fibroblast growth factor 23, high - sensitivity cardiac troponin, and left ventficular hypertrophy in CKD[J]. Am J Kidney Dis, 2013,61 ( 1 ) :67 -73.
  • 4Unsal A, Kose Budak S, Koc Y, et al. Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary ealcifieaton in chro- nic renal disease[J]. Kidney Blood Press Res, 2012,36(1) :55 -64.
  • 5Ketteler M, Biggar PH, Liangos O. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease [ J ]. Nephrol Dial Transplant, 2013,28 (4) :821 - 825.
  • 6Plischke M, Neuhold S, Adlbrecht C, et al. Inorganic phosphate and FGF- 23 predict outcome in stable systolic heart failure[ J]. Eur J Clin Invest, 2012 ,42(6) :649 -6456.
  • 7Guti6rrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease[ J]. Circula- tion, 2009,119 (19) :2545 - 2552.
  • 8李伟中,华川.探讨胱抑素C在非肾脏相关疾病中的应用价值[J].检验医学与临床,2013,10(22):3048-3050. 被引量:5
  • 9Dupont M, Wu Y, Hazen SL, et al. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular e- vents[J]. Circ Heart Fail, 2012,5(5) :602 -609.

二级参考文献20

共引文献4

同被引文献78

引证文献10

二级引证文献78

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部